VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of
Fulvestrant and CDK4/6 Inhibitors With or Without
Gedatolisib as First-Line Treatment in Patients With
HR-Positive and HER2-Negative Advanced Breast Cancer.
← Back to available clinical trials
